Light Matter Interaction Inc.

Published purpose

This project aims to develop and validate a novel platform for laser-assisted targeted drug delivery using LMI's proprietary picosecond mid-infrared laser technology. This technology enables precise ablation of tissues and when coupled to a microfluidic drug channel, the optic probe can deliver localized therapeutics with high resolution and minimal invasiveness. LMI holds foundational IP specific to this application covering fiberoptic laser-drug delivery systems in addition to the original core IP portfolio covering the unique laser tissue interaction. The platform will be validated in, phantom tissue, ex vivo and animal models, focusing on applications in high-value organ systems: prostate, brain, lung, and pancreas.